Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253265 | 0.80 | HTR1D (0.48) | HTR1DEGFRHTR2AHTR2CHTR2B | |
| SCHEMBL7253008 | 0.79 | HTR1D (0.62) | HTR1DHTR1BEGFRCLK4HTR2A | |
| SCHEMBL27649403 | 0.78 | HTR2C (0.57) | HTR1DHTR2AHTR2CHTR2BKMO | |
| SCHEMBL7256762 | 0.78 | HTR1D (0.64) | HTR1DHTR2AHTR2C | |
| SCHEMBL7253103 | 0.77 | HTR1D (0.67) | HTR1DEGFRBRD4 | |
| SCHEMBL17678355 | 0.74 | KMO (0.61) | HTR1DEGFRHTR2AHTR2CHTR2B | |
| SCHEMBL21026150 | 0.74 | HTR2A (0.41) | HTR1DEGFRHTR2AHTR2CHTR2B | |
| SCHEMBL31079475 | 0.73 | HTR2A (0.66) | HTR1DEGFRHTR2AHTR2CHTR2B | |
| SCHEMBL7253603 | 0.73 | KMO (0.59) | HTR1DEGFRHTR2AHTR2CHTR2B | |
| SCHEMBL27165371 | 0.73 | HTR2A (0.57) | EGFRHTR2AHTR2CHTR2BBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | claimed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | claimed |
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | disclosed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-6380242-B1 | FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS | NPS ALLELIX CORP. (CA) | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | CNR1, CNR2, KCNH1 | HTR1D 128/4885HTR1B 126/4885HDAC2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.